Get the Stockscreener App
23.95
2.44%
-0.60
After Hours:
24.35
0.40
+1.67%
Immunome Inc stock is traded at $23.95, with a volume of 1.17M.
It is down -2.44% in the last 24 hours and down -11.95% over the past month.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
See More
Previous Close:
$24.55
Open:
$24.44
24h Volume:
1.17M
Relative Volume:
0.89
Market Cap:
$2.72B
Revenue:
$4.02M
Net Income/Loss:
$-224.59M
P/E Ratio:
-10.07
EPS:
-2.3795
Net Cash Flow:
$-205.52M
1W Performance:
-10.67%
1M Performance:
-11.95%
6M Performance:
+17.63%
1Y Performance:
+152.64%
1-Day Range:
$23.55
$24.48
1-Week Range:
$23.55
$26.99
52-Week Range:
$8.925
$30.06
Immunome Inc Stock (IMNM) Company Profile
Name
Immunome Inc
Sector
Industry
Phone
610-321-3700
Address
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
23.95 | 2.80B | 4.02M | -224.59M | -205.52M | -2.3795 |
VRTX
Vertex Pharmaceuticals Inc
|
514.63 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
774.11 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
979.76 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
143.77 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
204.86 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-26 | Initiated | Barclays | Overweight |
| Feb-12-26 | Initiated | H.C. Wainwright | Buy |
| Dec-01-25 | Initiated | Truist | Buy |
| Sep-22-25 | Initiated | Goldman | Buy |
| Sep-05-25 | Initiated | Craig Hallum | Buy |
| Apr-02-25 | Initiated | Lake Street | Buy |
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Apr-30-24 | Initiated | JP Morgan | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Jan-29-24 | Initiated | Leerink Partners | Outperform |
| Dec-19-23 | Initiated | Wedbush | Outperform |
| Oct-29-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Immunome Inc Stock (IMNM) Latest News
Liquidity Mapping Around (IMNM) Price Events - Stock Traders Daily
Planned sale of 13,200 Immunome (NASDAQ: IMNM) shares disclosed in Rule 144 notice - Stock Titan
IMNM Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
GOOG: Alphabet IncOrdinary SharesClass C Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Immunome, Inc. Revenue Breakdown – NASDAQ:IMNM - TradingView
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
Immunome (NASDAQ:IMNM) Is In A Good Position To Deliver On Growth Plans - Moomoo
(IMNM) Volatility Zones as Tactical Triggers - Stock Traders Daily
Immunome (IMNM) Reports A Wider Loss, Is The Premium Valuation Justified? - Sahm
Immunome (IMNM) Update: Closes 0.98% Lower at $28.24 at the Close; Chart Watch: Traders Can Monitor the $26.83-$29.65 Range in the Current UpdateCommon Gap - siam.in
Immunome (IMNM) Results Review: EPS Clears the Reported Estimate for the Current Session; Closing Move - dars.gov.et
Should Immunome’s (IMNM) Rising Losses and ESOP Shelf Offering Require Action From Investors? - Sahm
Enterprise value to revenue forward of Immunome, Inc. – NASDAQ:IMNM - TradingView
Bank of America Corp DE Boosts Stake in Immunome, Inc. $IMNM - MarketBeat
IMNM|Immunome Inc|Price:28.520|Chg%:+0.440 - TradingKey
Enterprise value to EBIT forward of Immunome, Inc. – NASDAQ:IMNM - TradingView
Immunome (NASDAQ:IMNM) Sets New 12-Month HighShould You Buy? - MarketBeat
Immunome (IMNM) Faces A Valuation Test Following Earnings And Shelf Registration - Sahm
Immunome, Inc. (NASDAQ:IMNM) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
IMNM Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost Discipline at Pre-Revenue Oncology BiotechBuyback Announcement Report - vinanet.vn
Is Immunome’s (IMNM) Russell Exit Quietly Recasting Its Shareholder Base And Liquidity Story? - Sahm
Immunome director Isaac Barchas sells $940,453 in common stock - Investing.com
Dimensional Fund Advisors LP Decreases Stock Position in Immunome, Inc. $IMNM - MarketBeat
Immunome (IMNM) Is Up 8.7% After Wider Loss And ESOP Shelf Filing What’s Changed - simplywall.st
Immunome (NASDAQ:IMNM) Stock Rating Lowered by Wall Street Zen - MarketBeat
Immunome (IMNM) Q1 2026 Earnings: Narrower-than-Expected Loss Drives 2.95% Stock GainRevenue Miss Report - vinanet.vn
IMNM Q1 2026 Earnings: Narrower Net Loss Beats on Cost ControlPerformance Review - vinanet.vn
T. Rowe Price Investment Management (IMNM) discloses 17.4% Immunome ownership, key fund at 6.5% - Stock Titan
Sirenia Capital discloses 4.3% Immunome (IMNM) stake in Schedule 13G/A - Stock Titan
HC Wainwright Issues Negative Forecast for Immunome Earnings - MarketBeat
Craig-Hallum Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Immunome: Maintaining My 'Strong Buy' Rating With 2 Catalysts On The Horizon (IMNM) - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC) and Immunome (IMNM) - The Globe and Mail
Renaissance Technologies LLC Makes New Investment in Immunome, Inc. $IMNM - MarketBeat
Immunome gets FDA nod for varegacestat NDA, sets PDUFA date for April 2027 - Pluang
Immunome (NASDAQ:IMNM) Reaches New 12-Month High Following Analyst Upgrade - MarketBeat
Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 10,125 Shares - MarketBeat
Insider Selling: Immunome (NASDAQ:IMNM) Director Sells 11,048 Shares - MarketBeat
Insider Selling: Immunome (NASDAQ:IMNM) Director Sells $1,633,892.93 in Stock - MarketBeat
Immunome director Isaac Barchas sells over $2.1m in shares By Investing.com - Investing.com South Africa
Immunome director Isaac Barchas sells over $2.1m in shares - Investing.com
Immunome, Inc. Stock 12‑Month Price Target Raised to $36.31, Implies 38% Upside - TradingView
IMNM Maintains Buy Rating by Truist Securities -- Price Target R - GuruFocus
Immunome (NASDAQ:IMNM) Stock Price Expected to Rise, Truist Financial Analyst Says - MarketBeat
Immunome, Inc. Stock 12‑Month Price Target Raised to $36.15, Implies 38% Upside - TradingView
IMNM Maintains Outperform by Wedbush -- Price Target Raised to $35 - GuruFocus
Immunome stock hits 52-week high at 27.68 USD By Investing.com - Investing.com South Africa
Immunome stock hits 52-week high at 27.68 USD - Investing.com
Immunome Inc. SEC Filing (Aug 12, 2026) - Stock Titan
Evercore Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Immunome Inc Stock (IMNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunome Inc Stock (IMNM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Barchas Isaac | Director |
Aug 11 '26 |
Sale |
26.23 |
62,291 |
1,633,893 |
0 |
| Barchas Isaac | Director |
Aug 12 '26 |
Sale |
27.25 |
11,048 |
301,058 |
92,211 |
| Barchas Isaac | Director |
Aug 10 '26 |
Sale |
26.07 |
10,125 |
263,959 |
62,291 |
0.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):